<SEC-DOCUMENT>0001129928-21-000011.txt : 20210305
<SEC-HEADER>0001129928-21-000011.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210305120130
ACCESSION NUMBER:		0001129928-21-000011
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210305
FILED AS OF DATE:		20210305
DATE AS OF CHANGE:		20210305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		21717296

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6katm.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id0e5d79bc486441f832082459249019c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form 6-K</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the month of  March 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number 001-38512</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Translation of registrant's name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 1167 Kensington Crescent NW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calgary, Alberta, Canada T2N 1X7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:48.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;20-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;40-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id0e5d79bc486441f832082459249019c_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br>NUMBER</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="oncyatmpr.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release</a></font></div></td></tr></table></div><div style="-sec-extract:summary"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kirk Look </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look<br>Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>oncyatmpr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i26ccfbd797fd49269abbf53a4b8dd2f0_1"></div><div style="min-height:34pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10.15pt;margin-top:0.8pt;padding-left:1.7pt;padding-right:304.45pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:221px"></div><div style="margin-top:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:114%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%"> Establishes New At-The-Market Facility</font></div><div style="margin-top:12.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SAN DIEGO, CA and CALGARY, AB, March 5, 2021 -- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Inc. (NASDAQ&#58; ONCY) (TSX&#58; ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to US$80 million. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics the option to efficiently tap into the financial markets as needed to support ongoing business development activities and clinical trials, while bolstering management&#8217;s ability to negotiate potential business development agreements from a position of financial strength.</font></div><div style="margin-top:12.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In connection with the ATM, Oncolytics has filed a Prospectus Supplement with the Alberta Securities Commission and with the United States Securities and Exchange Commission, which supplements Oncolytics&#8217; Canadian short form base shelf prospectus dated June 12, 2020, and Oncolytics&#8217; shelf registration statement on Form F-10 declared effective on June 15, 2020 by the United States Securities and Exchange Commission. Sales of the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.</font></div><div style="margin-top:12.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">A copy of the Prospectus Supplement is available on SEDAR at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">www.sedar.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and on EDGAR at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or may be obtained upon request to Oncolytics&#8217; Investor Relations Department using the contact information set out below. Before you invest, you should read the Prospectus Supplement and accompanying base shelf prospectus and the other documents the Company has filed with the SEC for more complete information about the Company and the ATM offering. Alternatively, a copy of the Prospectus Supplement and accompanying base shelf prospectus are available upon request by contacting Canaccord Genuity LLC Attention&#58; Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, Attn&#58; Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospectus&#64;cgf.com.</font></div><div style="margin-top:13.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Oncolytics Biotech Inc.</font></div><div style="margin-top:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning &#34;cold&#34; tumors &#34;hot&#34; -- through innate and adaptive immune responses to treat a variety of cancers.</font></div><div style="margin-top:12.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. </font></div><div style="margin-top:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:114%">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements, including the Company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic, the anticipated benefits of the ATM to Oncolytics&#59; Oncolytics&#8217; plans for additional studies&#59; Oncolytics&#8217; preparation for a phase 3 registration study in metastatic breast cancer&#59; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, </font></div><div style="height:45.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:34pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:114%">including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.</font></div><div style="margin-top:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:114%"> </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.245%"><tr><td style="width:1.0%"></td><td style="width:39.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Company Contact </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Kirk Look</font></div><div style="padding-left:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Chief Financial Officer</font></div><div style="margin-top:0.1pt;padding-left:7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">403.670.7658</font></div><div style="margin-top:0.05pt;padding-left:7.2pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">klook&#64;oncolytics.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:82.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Investor Relations for Oncolytics</font></div><div style="margin-top:0.1pt;padding-left:82.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Timothy McCarthy</font></div><div style="padding-left:82.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">LifeSci Advisors</font></div><div style="margin-top:0.1pt;padding-left:82.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">917.679.9282</font></div><div style="margin-top:0.05pt;padding-left:82.8pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">tim&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i26ccfbd797fd49269abbf53a4b8dd2f0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:535.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
